Trilaciclib Dihydrochloride Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 300 mg
Reference Brands: Cosela (USA)
Category:
Oncology Cancer Care
Trilaciclib Dihydrochloride is available in Injection
and strengths such as 300 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Trilaciclib Dihydrochloride is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Trilaciclib Dihydrochloride can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Trilaciclib, marketed under the brand name Cosela, is a first-in-class CDK4/6 inhibitor designed to reduce the frequency of chemotherapy-induced bone marrow suppression in adults. It is indicated for patients receiving specific chemotherapy regimens for extensive-stage small cell lung cancer (SCLC). By inhibiting cyclin-dependent kinase 4/6, trilaciclib temporarily arrests hematopoietic stem and progenitor cells in the G1 phase of the cell cycle, thereby protecting bone marrow from chemotherapy-induced damage.
Trilaciclib is administered intravenously prior to chemotherapy under medical supervision and is intended to preserve bone marrow function without compromising the anticancer activity of chemotherapeutic agents. Its protective mechanism helps reduce the incidence of myelosuppression, including neutropenia, anemia, and thrombocytopenia, which can improve patient outcomes and allow for the continuation of scheduled chemotherapy cycles.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing